Eyetech CEO Keeps Faith In Wake Of Lucentis Bomb
The perhaps unreasonable power of preliminary data - especially when it's offered by an industry powerhouse - was proved once again late last month when mighty Genentech Inc. disclosed positive early figures from a Phase III trial with Lucentis against age-related macular degeneration (AMD).
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter